Table 3

Summary of immediate treatment patterns and responses in patients who progressed after discontinuation of PD-1 therapy*

Patients who relapsed (patient †)	Number of cycles/doses of initial anti-PD-1	Duration (months) of initial anti-PD-1	Time to progression (months)†	Response at discontinuation of initial anti-PD-1	Subsequent treatment	Number of cycles/doses of subsequent anti-PD-1	Duration (months) of subsequent anti-PD-1	Time to last follow-Up (months)‡	Vital status (alive (A)/deceased (D))
1	17	11.6	21.6	PR	Anti-PD-1	7	4.6	26.7	A
2	18	13.5	8.5	CR	Anti-PD-1	12	7.6	17.8	A
3	17	11	3.6	PR	Resection	–	–	6.7	A
4	15	10.4	3.7	SD	SBRT → Anti-PD-1	5	3.9	20.5	A
5	10	6.5	3.9	SD	Resection → Anti-PD-1	8	4.8	37.8	A
6	17	11.3	1.8	SD	Resection +radiation	–	–	7.1	D
7	16	10.3	0.7	SD	SRS	–	–	40	A
8	16	10.6	24.9	CR	Anti-PD-1	13	8.3	42.8	A
9	16	11	2.9	PR	Resection → Anti-PD-1	7	5.6	20.4	A
10	19	12.4	0.7	PR	Resection	–	–	31.7	A
11	11	7.6	30.9	PR	Resection → Anti-PD-1	12	10.4	43.3	A
12	20	13.6	6.7	PR	BRAF/MEK → Anti-PD-1	8	5.1	27.8	A
13	17	11.1	4.4	PR	SRS	–	–	19.3	A

*Further details in text.
†Time to progression from discontinuation of anti-PD-1.
‡Time to last follow-up from discontinuation of initial anti-PD-1.
CR, complete response; PD-1, programmed cell death protein 1; PR, partial response; SBRT, stereotactic body radiotherapy; SD, stable disease; SRS, stereotactic radiosurgery.